TH
Tharimmune, Inc.
THAR · NASDAQ
$3.54 +6.63% (+$0.22)
Piotroski F-Score Weak
2/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
-
N/A ROIC N/A
ROE N/A
ROA N/A
Debt
-
N/A Debt/Equity N/A
Current ratio N/A
Int. coverage N/A
Stability
37 /100
Moderate Beta 1.45x
Rev. volatility N/A
EPS volatility N/A
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na THAR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mark Wendland
Employees
2
Headquarters
Bridgewater